Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on December 20, 2019, regarding events occurring on December 19, 2019. The filing reports the effective date of a reverse stock split and a reduction in authorized shares approved by stockholders at a Special Meeting on December 9, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Reverse Stock Split: A 1-for-10 reverse stock split became effective on December 19, 2019, at 11:59 PM EST. Every 10 shares of issued and outstanding common stock automatically converted into one share.
- Authorized Shares Reduction: The total number of authorized common shares was reduced from 350 million to 120 million.
- Trading Adjustments: Trading on the NYSE American and Tel Aviv Stock Exchange (TASE) resumed on a split-adjusted basis under the symbol "PLX" on December 20, 2019, and December 22, 2019, respectively.
- Securities Adjustments: Proportionate adjustments were made to the exercise price and share count of outstanding stock options and the conversion ratio of outstanding 7.5% convertible promissory notes due 2021.
- New CUSIP: The new CUSIP number for the common stock is 74365A 309.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The primary contingency noted is the administrative process for stockholders holding physical certificates, who must exchange them for new post-split certificates via the transfer agent, American Stock Transfer & Trust Company, LLC.
Investor Verification Checklist
- Verify the new CUSIP number (74365A 309) for trading and record-keeping purposes.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-10 split.
- Review the impact of the split on the exercise price and share count of any held stock options.
- Check the conversion ratio adjustments for any held 7.5% convertible promissory notes due 2021.
- Ensure physical stock certificates are exchanged for new certificates if applicable.